Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment

被引：0
|
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Wu, L. [3 ]
Fang, J. [4 ]
Li, B. [5 ]
Han, L. [6 ]
Zhang, Y. [7 ]
Pan, H. [8 ]
Wang, Z. [4 ]
Sun, Y. [9 ]
Ye, F. [10 ]
Hu, Y. [11 ]
Yu, W. [12 ]
Zhou, H. [12 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Hunan Canc Hosp, Affiliated Canc Hosp Xiangya Sch Med, Dept Thorac Oncol 2, Changsha, Peoples R China
[4] Peking Univ Canc Hosp, Beijing, Peoples R China
[5] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[6] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China
[7] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[8] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[9] Jinan Cent Hosp, Jinan, Peoples R China
[10] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[11] Hubei Canc Hosp, Wuhan, Peoples R China
[12] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
anti-VEGF antibody; anti-PD-1; antibody; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P79.08
引用
收藏
页码：S649 / S649
页数：1
相关论文
共 50 条
  • [21] Transglutaminase 2(TG2) induces the intrinsic EGFR-TKI resistance in EGFR-mutant NSCLC
    Choi, Junyoung
    Yang, Hannah
    Kim, Sang-We
    Jung, Kyung Hae
    Park, Kang-Seo
    Lee, Dae Ho
    [J]. CANCER RESEARCH, 2017, 77
  • [22] Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors
    Chen, Y-Y.
    Zhu, Q-Q.
    Dai, L-J.
    Ding, Z-Y.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [23] Predicting duration of response to EGFR TKI among EGFR-mutant NSCLC patients.
    Sakr, Lama
    Kasymjanova, Goulnar
    Small, David I.
    Cohen, Victor
    Galvis, Luisa
    Pepe, Carmela
    Agulnik, Jason Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [25] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [26] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [27] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [28] Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI
    Wang, J.
    Wang, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S58 - S59
  • [29] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    [J]. JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [30] EGFR-mutant NSCLC cells upregulate the expression of inhibitory immune checkpoint CD24 under EGFR-TKI treatment
    Shiiya, Akihiko
    Noguchi, Takuro
    Ariga, Shin
    Ohhara, Yoshihito
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Akita, Hirotoshi
    [J]. CANCER SCIENCE, 2023, 114 : 427 - 427
12345